Pluristem Therapeutics - Rasio total nilai perusahaan marang pendapatan PLUR

The EV/Sales multiple history demonstrates the market valuation of Pluri Inc. (PLUR), where this metric equals 31773.97. Management is currently adapting the cell platform for the agricultural sector and foodtech. A team of experienced bioengineers is developing innovative placenta-based drugs. The technological foundation is provided by Israeli plants featuring autonomous power supplies and strict climate control within clean zones.
PLUR (pluri-biotech.com): rincian analitis lan laporan miturut indikator

The EV/Sales metric determines the enterprise value of a business, including net debt relative to sales volume, allowing for an assessment of the real value of assets without distortions from leverage. By analyzing current EV/Sales trends, an investor can identify if an asset is overbought, which is critical for Pluri Inc. (PLUR), whose capitalization relies on the patent protection of cell technologies but is limited by commercialization risks in medicine and foodtech.